PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression

Sample and data collection were funded by Cancer Research UK. Analysis was funded by Breast Cancer Now, the Rosetrees Trust, Guys & St Thomas’ Charity (CanHelp) and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London

Additional file 2: Figure S1. of PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression

Example of subclonal loss calculation using SNP array. Figure S2. Pure c-LCIS showing anueploidy and chromothripsis. Figure S3. Proportion of SCNA breakpoints in different subtypes of lobular cancer. (PDF 2813 kb

Additional file 1: Table S1a. of PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression

Clinico-pathological features of the discovery set - pure LCIS. Table S1b. Clinico-pathological features of the discovery set - inv-LCIS and ILC. Table S2a. Validation set: characteristics of the eight pure LCIS tumours that recurred. Table S2b. Validation set: characteristics of pure LCIS tumours that did not recur. Table S3. Common regions of gain /loss <10 Mb in size in classic lobular subtypes. Table S4. Regions of amplification occurring in more than one sample. Table S5a. Somatic mutations identified by whole exome sequencing in both the LCIS and ILC components in a single paired case. Table S5b. Somatic mutations identified by whole exome sequencing in ILC but not the LCIS component in a single paired case. Table S5c. Somatic mutations identified by whole exome sequencing in LCIS but not the ILC component in a single paired case. (DOCX 46 kb